Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer Therapy
Researchers from Memorial Sloan Kettering Cancer Center describe findings in breast cancer therapy
December 25th, 2008
Research findings, 'A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer,' are discussed in a new report. In this recent study, researchers in the United States conducted a study "To evaluate the efficacy and toxicity of erlotinib plus bevacizumab in patients with metastatic breast cancer (MBC), targeting the epidermal growth factor receptor (EGFR/HER1) and the vascular endothelial growth factor (VEGF) pathway. Thirty-eight patients with MBC were enrolled and treated at two institutions with erlotinib, a small molecule EGFR tyrosine kinase inhibitor (150 mg p.o. daily) plus bevacizumab, an anti-VEGF antibody (15 mg/kg i.v. every 3...
Source: Women's Health Weekly (2008-12-25)
|
